Search results for "6-tetrahydropyridine"

showing 5 items of 5 documents

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease

2011

Mitochondrial dysfunction and oxidative stress occur in Parkinson’s disease (PD), but little is known about the molecular mechanisms controlling these events. Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is a transcriptional coactivator that is a master regulator of oxidative stress and mitochondrial metabolism. We show here that transgenic mice overexpressing PGC-1α in dopaminergic neurons are resistant against cell degeneration induced by the neurotoxin MPTP. The increase in neuronal viability was accompanied by elevated levels of mitochondrial antioxidants SOD2 and Trx2 in the substantia nigra of transgenic mice. PGC-1α overexpression also protected against MP…

MaleSOD2Mice TransgenicSubstantia nigraMitochondrionBiologyNeuroprotectionCell LineMiceCellular and Molecular Neurosciencechemistry.chemical_compoundDopaminemedicineAnimalsNeurotoxinParkinson Disease SecondaryMolecular BiologyPGC-1α RSV SIRT1 MPTP Dopaminergic neurons Parkinson’s diseasePharmacologyMPTPDopaminergicBrainParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyDisease Models AnimalOxidative Stressnervous systemBiochemistrychemistry1-Methyl-4-phenyl-1236-tetrahydropyridineTrans-ActivatorsMolecular MedicineFemaleTranscription Factorsmedicine.drugCellular and Molecular Life Sciences
researchProduct

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

2002

Abstract The current concept of dyskinesia is that pulsatile stimulation of D-1 or D-2 receptors by l -DOPA or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. We now investigate the ability of two mixed D-1/D-2 agonists, namely pergolide (long-acting) and apomorphine (short-acting), to induce dyskinesia in drug-naive MPTP-lesioned primates, compared to l -DOPA. Adult common marmosets ( Callithrix jacchus ) were lesioned with MPTP (2 mg/kg/day sc for 5 days) and subsequently treated with equieffective antiparkinsonian doses of l -DOPA, apomorphine, or pergolide for 28 days. l -DOPA, apomorphine, …

Dyskinesia Drug-Inducedmedicine.medical_specialtyParkinson's diseaseL-DOPApergolideMotor ActivityapomorphineSeverity of Illness IndexDopamine agonistAntiparkinson AgentsLevodopaParkinson’s disease.Disability Evaluationchemistry.chemical_compoundParkinsonian DisordersDevelopmental NeuroscienceDopamineInternal medicineAnimalsMedicineMPTPPergolidemarmosetBehavior AnimalReceptors Dopamine D2business.industryReceptors Dopamine D1MPTPCallithrixmedicine.diseasenervous system diseasesApomorphineDisease Models AnimaldyskinesiaEndocrinologyNeurologychemistryDyskinesia1-Methyl-4-phenyl-1236-tetrahydropyridineDopamine receptorDopamine AgonistsSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drugExperimental Neurology
researchProduct

Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.

2010

Although generally considered a prototypical movement disorder, Parkinson's disease is commonly associated with a broad-spectrum of non-motor symptoms, including autonomic dysfunctions caused by significant alterations in catecholaminergic neurons of the peripheral sympathetic nervous system. Here we present evidence that alpha-synuclein is highly expressed by sympathetic ganglion neurons throughout embryonic and postnatal life and that it is found in tyrosine hydroxylase-positive sympathetic fibers innervating the heart of adult mice. However, mice deficient in alpha-synuclein do not exhibit any apparent alterations in sympathetic development. Sympathetic neurons isolated from mouse embryo…

Sympathetic nervous system1-Methyl-4-phenylpyridiniumα-Synuclein knockoutTyrosine 3-MonooxygenaseNeurotoxinsNeurotrophic factorSubstantia nigraBiologylcsh:RC321-571chemistry.chemical_compoundMiceCatecholaminesSympathetic Fibers PostganglionicParkinsonian DisordersNeurotrophic factorsmedicineNeurotoxinAutonomic gangliaAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryCells CulturedNeuronsGanglia SympatheticCell DeathMPTPSympathetic ganglionMice Mutant Strainsnervous system diseasesMPP+medicine.anatomical_structureNeurologychemistrynervous system1-Methyl-4-phenyl-1236-tetrahydropyridinePeripheral nervous systemSympathetic nervous systemNerve Degenerationalpha-SynucleinCatecholaminergic cell groupsPeripheral nervous systemNeuroscienceNeurobiology of disease
researchProduct

Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from …

2010

In the present work we report the generation of a new line of alpha-synuclein (alpha-SYN) transgenic mice in which the human wild-type alpha-SYN cDNA is expressed under the control of a tyrosine hydroxylase (TH) promoter. We provide evidence that the ectopic protein is found in TH expressing neurons of both central and peripheral nervous systems. The transgene is expressed very early in development coinciding with the activity of the TH promoter and in the adult brain the human protein distributes normally to the nerve endings and cell bodies of dopaminergic nigral neurons without any evidence of abnormal aggregation. Our results indicate that expression of human wild-type alpha-SYN does no…

medicine.medical_specialtySympathetic Nervous SystemTyrosine 3-MonooxygenaseTransgeneMice Transgenicchemistry.chemical_compoundMiceCatecholaminesDopamineMesencephalonInternal medicinemedicineNeurotoxinAnimalsHumansTransgenesPromoter Regions GeneticCells CulturedDopamine transporterNeuronsDopamine Plasma Membrane Transport ProteinsTyrosine hydroxylasebiologyCell DeathGeneral NeuroscienceMPTPDopaminergicBrainEndocrinologynervous systemchemistry1-Methyl-4-phenyl-1236-tetrahydropyridineOrgan Specificitybiology.proteinalpha-SynucleinCatecholaminergic cell groupsmedicine.drugNeuroscience
researchProduct